A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

Condition:   Hepatitis C Virus InfectionInterventions:   Drug: Daclatasvir;   Drug: Asunaprevir;   Drug: Ribavirin;   Biological: pegIFNα-2b;   Drug: TelaprevirSponsor:   Bristol-Myers SquibbActive, not recruiting - verified April 2013

Source: ClinicalTrials.gov - October 29, 2012 Category: Research Source Type: clinical trials